Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Quinism Foundation Expresses Concern That Department of Veterans Affairs (VA) Disability Examiners Are Misattributing Chronic Adverse Effects of Mefloquine to PTSD
  • USA - English

Although DSM-5 Diagnostic Criteria Exclude the Diagnosis of PTSD if Symptoms Such as Insomnia and Nightmares Are Attributable to Medication Effects, VA Disability Examiners Do Not Routinely Screen Veterans for a History of Symptomatic Mefloquine Exposure


News provided by

The Quinism Foundation

Nov 29, 2018, 03:00 ET

Share this article

Share toX

Share this article

Share toX

WHITE RIVER JUNCTION, Vt., Nov. 29, 2018 /PRNewswire-PRWeb/ -- The Quinism Foundation has sent correspondence to Dr. Paul R. Lawrence, Under Secretary for Benefits at the Department of Veterans Affairs (VA), expressing concern that disability examiners may be misattributing adverse effects from the antimalarial drug mefloquine to PTSD in VA medical disability examinations.

"DSM-5 PTSD Criterion H requires that the examiner determine that the disturbance is not attributable to the physiological effects of a medication," said Remington Nevin, MD, MPH, DrPH, executive director of The Quinism Foundation. "We are concerned that this criterion is being widely assumed by examiners without due consideration for the possible effects of mefloquine exposure."

Mefloquine has been widely used by the Department of Defense (DoD), particularly for the prevention (or prophylaxis) of malaria among U.S. military personnel, since it was licensed by the U.S. Food and Drug Administration (FDA) in 1989. In 2013, after nearly a quarter-century of use by DoD, the FDA warned that mefloquine can cause long-lasting and even permanent neuropsychiatric adverse effects [1]. The DoD has since declared mefloquine "a drug of last resort," and has all but eliminated the drug's use [2].

According to the FDA, chronic neuropsychiatric adverse effects from mefloquine exposure include insomnia, depression, anxiety, and paranoia, among others. Authors at the U.S. military's Walter Reed Army Institute of Research (WRAIR) [3], where mefloquine was developed, have noted that "mefloquine toxicity can persist for several years after exposure has been discontinued, with little to no abatement in symptoms over time. Furthermore, given the overlapping symptoms of post-traumatic stress disorder [PTSD] and mefloquine toxicity, it can be challenging to distinguish between the two diagnoses."

In its correspondence, which was shared with executives at Logistics Health Incorporated, QTC Management Incorporated, and VetFed Resources Incorporated (three federally-contracted providers of VA medical disability examinations), Dr. Nevin shared results from The Quinism Foundation's recent review of veterans' disability medical examination documentation.

"The Quinism Foundation has recently reviewed a number of PTSD disability benefits questionnaires (DBQ) completed by examiners in which Criterion H was deemed to have been met without documentation that the examiner considered the possible physiological effects of mefloquine in contributing to the disturbance," wrote Dr. Nevin. "In many cases, these examiners concluded Criterion H was met even when the veteran specifically attributed several of their PTSD Criterion B-E symptoms, such as nightmares, insomnia, irritability, and anger, to chronic effects of their mefloquine exposure, rather than to one or more Criterion A traumatic stressors. In several cases, available documentation reliably places the onset of these symptoms well prior to any Criterion A traumatic stressors, and within days following the veteran's initial exposure to mefloquine."

"Although the current PTSD DBQ specifically advises examiners to 'NOT mark symptoms… that are clearly not attributable to the Criterion A stressor/PTSD,' and warns that 'overlapping symptoms clearly attributable to other things' should be noted elsewhere, there appears to be no formal mechanism for examiners conducting VA medical disability examinations to screen veterans for symptoms that could be due to mefloquine exposure," wrote Dr. Nevin.

In its correspondence, The Quinism Foundation encouraged examiners to formally screen recent veterans for a history of symptomatic exposure to mefloquine during VA medical disability examinations.

"Screening for such symptomatic exposure during a medical disability examination can be as quick and simple as asking the veteran 'Did you take mefloquine', and if so, 'While you were taking the drug, did you experience one or more of these symptoms?'," wrote Dr. Nevin. "If the veteran reports symptomatic exposure, examiners should retain an index of suspicion that any chronic neurologic or psychiatric symptoms, including those reported, could represent effects of mefloquine poisoning, specifically, symptoms of a medical condition also known as chronic quinoline encephalopathy or neuropsychiatric quinism."

"In such cases, a DSM-5 diagnosis of a medication-induced anxiety, sleep, mood, or psychotic disorder may be more appropriate than a comparable diagnosis, such as PTSD, which is excluded by DSM-5 criteria if the disturbance is due to the lasting physiological effects of a medication," wrote Dr. Nevin.

In its correspondence, The Quinism Foundation noted that it has recently begun partnering with several health care organizations, including in the U.K. [4] and Canada [5], to make available its two-question White River Mefloquine Instrument (WRMI-2), to facilitate screening for symptomatic mefloquine exposure in veteran populations. The Quinism Foundation has previously called upon the VA [6], as well as Veterans Affairs Canada (VAC) [7], to screen all recent U.S. and Canadian veterans to improve the quality of medical care provided by these organizations.

About The Quinism Foundation

The Quinism Foundation, founded in January 2018, in White River Junction, Vermont, promotes and supports education and research on quinism, the family of medical disorders caused by exposure to quinoline drugs, including mefloquine and tafenoquine.

Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist. He is author of more than 30 scientific publications on malaria and the quinoline antimalarials, including "Screening for Symptomatic Mefloquine Exposure Among Veterans With Chronic Psychiatric Symptoms," published in the journal Federal Practitioner (https:// https://www.mdedge.com/fedprac/article/132560/mental-health/screening-symptomatic-mefloquine-exposure-among-veterans).

1. U.S. Food and Drug Administration. FDA approves label changes for antimalarial drug mefloquine hydrochloride due to risk of serious psychiatric and nerve side effects. July 29, 2013. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM362232.pdf.
2. Nevin RL. Screening for Symptomatic Mefloquine Exposure Among Veterans With Chronic Psychiatric Symptoms. Federal Practitioner. 2017;34(3):12-14.
3. Livezey J, Oliver T, Cantilena L. Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine. Drug Safety - Case Reports. 2016;3(1):7.
4. The Quinism Foundation. The Quinism Foundation Partners with the National Centre for Trauma to Screen U.K. Veterans for Symptomatic Mefloquine Exposure. July 30, 2018. https://quinism.org/press-releases/the-quinism-foundation-partners-with-the-national-centre-for-trauma-to-screen-u-k-veterans-for-symptomatic-mefloquine-exposure.
5. The Quinism Foundation. The Quinism Foundation Partners with Lifemark Health Group to Identify Canadian Veterans at Risk from Exposure to the Antimalarial Drug Mefloquine. September 17, 2018. https://quinism.org/press-releases/the-quinism-foundation-partners-with-lifemark-health-group-to-identify-canadian-veterans-at-risk-from-exposure-to-the-antimalarial-drug-mefloquine.
6. The Quinism Foundation. The Quinism Foundation Calls on the Department of Veterans Affairs to Screen Recent Veterans for Symptomatic Mefloquine Exposure. May 29, 2018. https://quinism.org/press-releases/the-quinism-foundation-calls-on-the-department-of-veterans-affairs-to-screen-recent-veterans-for-symptomatic-mefloquine-exposure.
7. The Quinism Foundation. The Quinism Foundation Calls on Veterans Affairs Canada to Screen Recent Canadian Veterans for Symptomatic Mefloquine Exposure. September 19, 2018. https://quinism.org/press-releases/the-quinism-foundation-calls-on-veterans-affairs-canada-to-screen-recent-canadian-veterans-for-symptomatic-mefloquine-exposure.

SOURCE The Quinism Foundation

Modal title

The Quinism Foundation
The Quinism Foundation
The Quinism Foundation

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.